Podcasts about endometrial cancer

Epidemiology is the study of how and why diseases affect different groups of people, and what the science increasingly shows is that preventing disease and preserving health are deeply connected. In this episode, we focus on endometrial cancer, a disease where many risk factors are within our control. We speak with Immaculata De Vivo, PhD, professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health, about how lifestyle factors like movement, nutrition, stress management, and social connection can influence our biology and long-term health. We also explore the biological impact of chronic stress in cancers like endometrial cancer and discuss how listeners can feel more informed, empowered, and proactive during healthcare visits. Credits Host: Neha Pathak, MD, FACP, DipABLM Producer/Editor: Lauren Summers Show Notes: Lauren Summers Guest: Immaculata De Vivo, PhD See omnystudio.com/listener for privacy information.

What happens when the womb is treated as separate from the rest of women's health? In this episode of hol+, Dr. Taz sits down with Dr. Kemi Doll, double board-certified gynecologic oncologist, equity scientist, researcher, coach, and author of A Terrible Strength: The Hidden Crisis of the Black Womb and Your Survival Guide to Healing, for a powerful conversation about womb health, uterine cancer, fibroids, HRT, health equity, and why so many women are still being taught to normalize symptoms that deserve care.Together, they explore why womb health is not only about pregnancy, fertility, or menopause, but a lifelong part of women's physical, emotional, hormonal, and whole-body health. Dr. Doll shares how her grandmother's death in childbirth, her mother's near-death experience, and her own work as a gynecologic cancer surgeon shaped her mission to bring the uterus back into the center of women's health.Dr. Taz and Dr. Doll also discuss why uterine cancer is rising, why Black women are twice as likely to die after a uterine cancer diagnosis, and how gaps in research, screening, and diagnostic tools may leave women of color especially vulnerable. They unpack the role of ultrasound, endometrial thickness, post-menopausal bleeding, and why women need clearer conversations with their providers when something feels off.This conversation also takes a closer look at the explosion of hormone replacement therapy, or HRT, and the questions every woman with a uterus should be asking. Dr. Doll explains why estrogen without proper progesterone protection can increase uterine cancer risk, why some women may not understand the role progesterone plays, and why monitoring the uterus matters when using hormones.If you're listening to this and thinking, “I know something is off in my body, but I don't know where to start,” join the Circle here:

Endometrial cancer is the most common gynecologic cancer in the United States and the fourth most common cancer affecting women. One of its most important warning signs – abnormal vaginal bleeding or spotting – is something many women experience and may dismiss. While survival rates exceed 95%, both overall incidence and mortality rates are rising. In this episode, we speak with Ursula A. Matulonis, MD, chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, about the symptoms of endometrial cancer, the role family history plays in risk, and the lifestyle habits that may help lower your chances of developing the disease. Credits Host: Neha Pathak, MD, FACP, DipABLM Producer/Editor: Lauren Summers Show Notes: Lauren Summers Guest: Ursula A. Matulonis, MD See omnystudio.com/listener for privacy information.

In recognition of Endometrial Cancer Awareness Month, this episode features Jennifer Graham, a three-time cancer patient and patient advocate with the Marathon of Hope Cancer Centres Network (MOHCCN). Jennifer shares her experiences navigating breast, endometrial, and ovarian cancer, reflecting on the emotional realities of diagnosis, treatment, survivorship, and living with uncertainty. Together, we discuss the importance of support systems, how cancer shaped her perspective on life and advocacy, and the role of patient voices in improving cancer research and care. Through her story, Jennifer offers an honest and hopeful conversation about resilience, community, and moving forward through even the most difficult moments.For more information on the Gynecologic Cancer Initiative, please visit https://gynecancerinitiative.ca/ or email us at info@gynecancerinitiative.ca  Where to learn more about us:  Twitter – @GCI_Cluster Instagram – @gynecancerinitiative Facebook – facebook.com/gynecancerinitiativeTikTok – @gci_gosh

A concise overview of major risk drivers (obesity, hormone exposure, hereditary syndromes), common presentations, and next-step evaluation to help hospital teams improve early detection and care coordination.  Learn more about Megan Hutchcraft, MD 

GPs Rebecca and Sarah are joined by Professor Emma Davidson to discuss the latest on endometrial cancer in primary care. The conversation covers non-invasive diagnostic innovations, the realities of hysteroscopy, and when to refer for unscheduled bleeding on HRT. They delve into key risk and protective factors, including obesity, family history, and the impact of hormone therapy and GLP-1 medications. The team also highlights the role of patient education, the challenge of differentiating bleeding sources, and emerging clinical guidance, such as recognising Lynch syndrome and the relevance of the LEGOC acronym.If you loved this episode and would like to hear more like this, please send your review to the-christie.gatewayc@nhs.net and share the series with a colleague.GPs Talk Cancer is the podcast series from GatewayC. GatewayC is the free early cancer diagnosis resource funded by the NHS and is part of The Christie NHS Foundation Trust. View the full shownotes for this episode at Podcast - GatewayCProduced by GatewayC and Listening Dog Media.DISCLAIMER: We know this podcast might be of interest to anybody, however it is aimed at primary care health professionals. All patient cases are based on real stories from our clinical practice as GPs. They are fully anonymised with no identifiable patient data. All featured statistics are accurate at the time of recording. All views expressed by guest speakers are their own. Hosted on Acast. See acast.com/privacy for more information.

Proceedings from a live event on April 11, 2026, held during the 2026 SGO Annual Meeting on Women's Cancer and moderated by Dr Ritu Salani, including the following topics: Biology of Advanced Endometrial Cancer (EC); Optimal Approach to Biomarker Assessment in Patients with Newly Diagnosed Disease — Dr Backes (0:00) Current Up-Front Chemoimmunotherapeutic Approaches for Advanced EC — Dr Powell (25:18) Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy in Advanced EC — Dr Salani (59:02) CME information and select publications

Editor's Choice:  Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleedingEditorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practiceHosted by: Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USAFeaturing: Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USAJohn B. Kisiel, MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USAJoy M. Davis MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Lisa Beck, a fitness-focused director of operations from Keller, Texas, was so healthy she wasn't even nervous about her biopsy. The call telling her she had endometrial cancer stopped her in her tracks. What followed was two years of navigating conflicting diagnoses (serous vs. endometrioid cancer), doctors eager to remove everything they could, and her own fierce determination to slow down and make informed decisions. She sought opinions at Texas Oncology, MD Anderson, and Memorial Sloan Kettering, eventually discovered a BRCA1 mutation, and pursued integrative treatments in Tijuana alongside conventional care. Three years cancer-free, Lisa now leads a HealingStrong group in Keller and is newly addicted to pickleball.HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please take advantage of our FREE resources below to help you along your health and healing journey:Support Group DirectoryHolistic Curriculum - Participant GuideSupport Our Mission - DonateAdditional Health ResourcesListen to Previous EpisodesWebsite: healingstrong.org

Endometrial cancer accounts for 95% of uterine cancers, which are the fourth most common cancer in women in the US. Author Karen McLean, MD, PhD, of Roswell Park Comprehensive Cancer Center joins JAMA Senior Editor Karen Lasser, MD, MPH, to discuss the current evidence about diagnosis and treatment of endometrial cancer. Related Content: Endometrial Cancer

New episode alert!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ATW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 15, 2027.Charting New Territories in Endometrial Cancer Care: Insights for Personalizing Treatment With Biomarker-Informed Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent medical education grants from GSK and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ATW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 15, 2027.Charting New Territories in Endometrial Cancer Care: Insights for Personalizing Treatment With Biomarker-Informed Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent medical education grants from GSK and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ATW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 15, 2027.Charting New Territories in Endometrial Cancer Care: Insights for Personalizing Treatment With Biomarker-Informed Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent medical education grants from GSK and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ATW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 15, 2027.Charting New Territories in Endometrial Cancer Care: Insights for Personalizing Treatment With Biomarker-Informed Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent medical education grants from GSK and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

In 2016 at age 55, Karen was fit, but stressed with a very demanding job, after going through a difficult divorce a few years earlier. She started to experience heavy bleeding and after a few months of investigation and finally a biopsy, she was (shockingly) told she had stage 3C Clear Cell endometrial cancer. Clear Cell is a very rare and extremely aggressive cancer, so she felt both hopeless and helpless.  Karen knew treatment was limited as Clear Cell doesn't really respond to chemotherapy, so she decided to try everything she could. She had extensive pelvic surgery, some chemotherapy, 42 rounds of radiotherapy and brachytherapy but despite it all, 6 months later, the disease had spread to her lungs. It was then she decided that she would be among the 6% who survived longer than 5 years with this diagnosis and began to do her research. That included reading Radical Remission, which gave her so much HOPE.  Listen to this episode to learn how Karen has been NED since 2022. To connect with Karen - Instagram @thenewhealingcompany ___________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com.   To learn more about Radical Remission health coaching with Liz or Karla, Click Here   Join our mailing list and you'll receive our free eBook, Kickstart Your Healing: 20 Radical Remission Tips, as a special thank you for joining. Subscribe Here   To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here. To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. Follow us on Social Media: Facebook  Instagram YouTube ____ Nestled in the pristine, natural beauty of British Columbia, The Healing Oasis stands as Canada's first-of-its-kind cancer wellness retreat, where hope reignites and the body is empowered to heal. Here, our renowned naturopathic cancer expert, Dr. Sean Ceaser, designs a fully personalized protocol of advanced, non-toxic therapies—including high-dose IVs like mistletoe and vitamin C, cutting-edge hyperthermia, PEMF, oxygen therapy, red light, and more. Savor daily organic, cancer-fighting meals, rest deeply in serene cabins, immerse in restorative activities like forest walks and yoga, drink mineral-rich living water, and receive emotional support in a peaceful sanctuary that combines world-class care with profound nature immersion to reduce side effects, boost vitality, and spark radical healing. Your journey to feeling alive again begins today at thehealingoasis.ca. Learn More about The Healing Oasis: Website   Testimonials Video Overview

What clinical trials led to updates in the treatment strategies for advanced/recurrent endometrial cancer? Credit available for this activity expires: 3/9/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/beyond-update-advanced-recurrent-endometrial-cancer-how-2026a10006up?ecd=bdc_podcast_libsyn_mscpedu

- Overview of Endometrial Cancer, Including Diagnosing & Staging - Current Standard of Care - New Treatment Approaches - New Treatment for Metastatic Endometrial Cancer - The Role of Precision Medicine, Targeted Treatments & Immunotherapy - The Important Role of the Pathologist - Genetic & Biomarker Testing - Clinical Trials: How Research Increases Treatment Options - Managing Treatment Side Effects, Symptoms, Discomfort & Pain - The Benefits of Communicating with Your Health Care Team - Questions for Our Panel of Expert Speakers

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School, both in Boston, Massachusetts. In this episode, Dr Matulonis sat down with guest Panagiotis (Panos) A. Konstantinopoulos, MD, PhD, to discuss the different subtypes of endometrial cancer and treatment developments for this disease. Dr Konstantinopoulos is the director of Translational Research in the Division of Gynecologic Oncology, the director of the Mellen and Eisenson Family Center for BRCA and Related Genes, and the Velma Eisenson Chair for Clinical and Translational Research at Dana-Farber Cancer Institute; as well as a professor of medicine at Harvard Medical School. Drs Matulonis and Konstantinopoulos explained that patients with mismatch repair–deficient (dMMR) tumors substantially benefit from a decreased risk of progression or death when immunotherapy is added to standard therapy. They noted that immunotherapy appears important for the management of dMMR tumors, even those in earlier stages or in patients who have no measurable disease remaining after surgery. For MMR-proficient (pMMR) tumors, Drs Matulonis and Konstantinopoulos highlighted that PD-1 blockade combined with chemotherapy improves survival vs chemotherapy alone, but that this benefit is not as substantial as that seen in dMMR disease. Crucially, they reported that if a pMMR tumor has no measurable disease after surgery, adding immune checkpoint blockade does not appear beneficial. They stated that tailored treatment approaches are key for managing pMMR disease subtypes. They added that hormonal therapy may be used upfront for slow-growing, estrogen receptor–positive metastatic disease. They continued by saying that DNA damage and replication stress are critical targets, particularly in p53-mutated tumors, like uterine serous cancers. Furthermore, they stressed that although the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu) is highly effective in HER2-positive tumors, treatment with this agent requires monitoring for toxicities, including interstitial lung disease and decreased ejection fraction.

Guest: Brian Slomovitz, MD Endometrial cancer is rising in incidence, with mortality now surpassing that of ovarian cancer. Hear from Dr. Brian Slomovitz as he explores evolving molecular classifications, treatment challenges, and the urgent need to address racial disparities in care. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Guest: Brian Slomovitz, MD Endometrial cancer is closely tied to modifiable risk factors such as obesity, diabetes, hypertension, and insulin resistance—all components of a chronic inflammatory state that heightens cancer susceptibility. Dr. Brian Slomovitz discusses how lifestyle interventions and emerging therapies may reduce cancer recurrence. He's the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Join host Talaya Dendy on Navigating Cancer TOGETHER for another inspiring conversation with the truly remarkable Wenora Johnson.Wenora is a three-time cancer survivor (colorectal, endometrial, and basal cell carcinoma) and a passionate patient and research advocate. In this episode, she shares her incredible, decades-long journey and how her background in the Navy instilled the grit and discipline she needed to face these health challenges.What You'll Learn:Lynch Syndrome & Genetic Testing: Wenora discusses the pivotal role that genetic testing and the discovery of Lynch syndrome played in her early detection and survival. This segment is a must-listen for anyone considering testing.The Power of Policy Change: Hear about Wenora's dedicated work in patient advocacy, including her efforts to push for policy changes that would lower the recommended age for initial colonoscopies.Self-Advocacy & Resilience: Get real-world advice on how to stand up for yourself in the healthcare system and how Wenora harnessed her inner resilience to overcome multiple diagnoses.Caregiving Insights: The conversation touches on the often-overlooked challenges and realities faced by caregivers.Whether you are a patient, a caregiver, or simply looking for a story of extraordinary determination, Wenora's insights and message of hope are invaluable. Don't miss this episode!✨Episode Highlights:02:12 Meet Wenora Johnson: A Three-Time Survivor06:22 The Impact of Lynch Syndrome on Her Journey10:08 Why Genetic Testing Is So Important16:04 Fighting for Change: Advocacy and Policy33:00 Understanding Caregiving Challenges36:19 Tips for Self-Advocacy and Building Resilience43:19 Wenora's Final Thoughts and Resources (FORCE)Transcript: https://bit.ly/podscript177Resource: FORCE, https://www.facingourrisk.org/about-usInspired by Wenora's resilience? Start your journey with calm. Download your FREE Guided Meditation: "Calming Your Mind After a Cancer Diagnosis." Get inner peace now! https://www.ontheotherside.life/guidedmeditation

Visceral fat — the deep fat around your organs — acts like a hormone-producing organ that fuels inflammation, disrupts metabolism, and increases the risk of aggressive endometrial cancer New research shows that fat activity, not fat amount, predicts cancer severity, meaning even women with moderate weight face higher risk if their fat is metabolically active Chronically inflamed visceral fat releases cytokines, fatty acids, and signaling molecules that promote tumor growth, insulin resistance, and immune suppression, creating a biological environment where cancer thrives You can calm overactive fat by eliminating seed oils, lowering stress hormones like cortisol, and supporting mitochondrial function through healthy carbs, restorative sleep, and natural progesterone balance Restoring metabolic health through consistent, daily habits helps deactivate inflammatory fat, lower cancer risk, and rebuild your body's natural resilience and energy production

Dr Kathleen N Moore from OU Health Stephenson Cancer Center in Oklahoma City, Oklahoma, and Dr Matthew A Powell from the Washington University School of Medicine in St Louis, Missouri, discuss recent updates on available and novel treatment strategies for endometrial cancer. CME information and select publications here.

Featuring perspectives from Dr Kathleen N Moore and Dr Matthew A Powell, including the following topics: Introduction: A Pan-tumor Perspective on Microsatellite Instability (MSI)-High Disease — Immunotherapy for Localized Disease (0:00) Case: A woman in her early 60s with mismatch repair-deficient metastatic endometrial cancer (EC) and multiple positive metastases — Shachar Peles, MD (8:18) Case: A woman in her mid 60s with recurrent EC and a BRCA mutation — Stephen "Fred" Divers, MD (12:17) Data Review: Immune Checkpoint Inhibitors (15:26) Case: A woman in her early 30s with Stage I mismatch repair-proficient EC and multiple pulmonary metastases after receiving fertility treatments — Kellie E Schneider, MD (28:22) Case: A woman in her early 80s with EC and high blood pressure — Syed F Zafar, MD (34:24) Case: A postmenopausal woman in her late 60s with recurrent HER2-positive EC and unresectable carcinomatosis — Lyndsay J Willmott, MD (38:18) Case: A woman in her late 60s with EC and pericarditis — Karim ElSahwi, MD (44:28) Data Review: Novel Antibody-Drug Conjugates (51:38) Case: A woman in her early 70s with metastatic MSI-stable, HER2-negative EC with PI3 kinase and FGFR mutations wants to avoid treatment with chemotherapy — Victoria Giffi, MD (55:01) CME information and select publications

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Case-Applications-in-Multidisciplinary-Care-for-Endometrial-Cancer/39298/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Role-of-Predictive-Biomarkers-in-Endometrial-Cancer/39293/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Managing-Immune-Related-Adverse-Events-in-Cervical-and-Endometrial-Cancer/39296/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Evidence-Base-for-Treatment-Strategies-for-Endometrial-Cancer-After-Disease-Progression-and-Interdisciplinary-Collaboration/39295/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Evidence-Base-for-First-Line-Treatment-Strategies-for-Endometrial-Cancer-and-Delivering-Guideline-Concordant-Care/39294/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

What are the subtle signs of gynae cancers we might be dismissing as something else? Could the type of pan you cook with help your iron deficiency? And are your allergy medications causing dryness... down there? We know hearing the word 'cancer' can be a frightening experience. But facing that fear with facts is the first step. We’re here to arm you with the information you need – from spotting subtle symptoms to understanding risk factors – so you can feel empowered to advocate for your own health and persist in getting the answers you deserve. In this episode, we talk to medical oncologist Professor Clare Scott, Chair of Australia New Zealand Gynaecological Oncology Group and one of Australia’s leading cancer researchers and clinicians. We discuss the three major types of gynae cancers: ovarian, endometrial and cervical, why your endo and PCOS aren’t cause for cancer concern and the effect of ovarian cancer on your fertility. We also talk about why you might be iron deficient and the simple kitchen tools that could help boost your iron levels, especially if you don't eat a lot of red meat. Plus, Dr. Mariam explains misconceptions around the HPV virus and the importance of self-collected HPV testing in Australia's mission to eliminate cervical cancer. THE END BITS All your health information is in the Well Hub. We understand that conversations about cancer can be difficult, whether you're navigating your own diagnosis, supporting a loved one, or remembering someone you've lost. If today's episode has brought up difficult feelings, please reach out. The Cancer Council offers a confidential support line staffed by specialist nurses, and you can call them on 13 11 20. For more specific information on the topics we discussed today, organisations like Australian Gynaecological Cancer Foundation, Ovarian Cancer Australia and the Australian Cervical Cancer Foundation provide incredible support and resources for patients and their families. And if you just need to talk to someone immediately, you can always call Lifeline on 13 11 14. Remember to be kind to yourself, and please don't hesitate to seek support. GET IN TOUCH Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. Support independent women’s media by becoming a Mamamia subscriber CREDITS Hosts: Claire Murphy and Dr Mariam Guest: Professor Clare Scott Senior Producers: Claire Murphy and Sally Best Audio Producer: Scott Stronach Video Producer: Julian Rosario Social Producer: Elly Moore Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Information discussed in Well. is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional.Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.

Please visit answersincme.com/UDT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic oncology discusses primary chemoimmunotherapy regimens in advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Apply biomarker testing results to guide initial treatment decisions in advanced endometrial cancer; Select the optimal therapy for a given patient with endometrial cancer, based on the latest evidence; Design patient-centered, multidisciplinary care plans that support treatment continuity and patient survivorship.

A gynaecological cancer diagnosis shouldn't take away the right to plan your future. This episode delves into surgical options and fertility considerations, highlighting minimally invasive versus open surgery, fertility-sparing treatments, hormonal therapy pathways, and the emotional and reproductive impacts of surgical decisions.Through lived experience from Mina and expert guidance from Professor Alison Brand AM, we explore how surgical innovations can support both health and future family planning. Ask questions, explore your options, and take an active role in your care.

In this episode of the ACRO Podcast CURiE Conversations edition, Dr. Jenna Kahn speaks with authors Dr. Scott Silva and med student Caitlin Reichard about their published article, "Dosimetry, Toxicity, and Outcomes of Medically Inoperable Endometrial Cancer Treated With Definitive External Beam Radiation Therapy and Brachytherapy." Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science. Read the full article here: https://www.cureus.com/articles/366834-dosimetry-toxicity-and-outcomes-of-medically-inoperable-endometrial-cancer-treated-with-definitive-external-beam-radiation-therapy-and-brachytherapy#!/

In our exclusive interview, Dr Chase discussed the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies. For first recurrences, she explained that carboplatin and paclitaxel with pembrolizumab (Keytruda) or dostarlimab-gxly (Jemperli) is recommended for patients with mismatch repair–deficient (dMMR) disease, whereas those with MMR-proficient (pMMR) disease may benefit from carboplatin, paclitaxel, and pembrolizumab (Keytruda) or lenvatinib (Lenvima). She also highlighted findings from the phase 3 RUBY trial (NCT03981796) that supported the FDA approval of dostarlimab, showing significant improvements in progression-free and overall survival in both dMMR and pMMR patients. Chase also noted the rising incidence of endometrial cancer, its deadly nature, and the importance of clinical trials for advancing treatment options. 

Guest: Ann Klopp, M.D., Ph.D. The recent NRG0238 trial evaluated whether adding chemotherapy to radiation improves outcomes in patients with localized endometrial cancer recurrences. Hear from Dr. Ann Klopp as she explains the findings and how they could shift practice patterns for patient care. Dr. Klopp is a Professor of Radiation Oncology, the Director of Brachytherapy, and the leader of the gynecologic section in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center in Houston.

Guest: Ann Klopp, M.D., Ph.D. Endometrial cancer treatment is continuing to evolve, with surgery guiding initial decisions and new evidence showing that adding immunotherapy significantly improves outcomes in advanced disease. But key questions remain around tailoring regimens to individual patients. Dr. Ann Klopp highlights the latest advances and challenges in management, particularly in patients with pelvic recurrences. Dr. Klopp is a Professor of Radiation Oncology, the Director of Brachytherapy, and the leader of the gynecologic section at the University of Texas MD Anderson Cancer Center in Houston.

Show notes and links: https://www.chrisbeatcancer.com/from-hospice-to-healed-julie-masons-endometrial-cancer-journey

Dr Shannon Westin from the University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for ovarian and endometrial cancer. CME information and select publications here.

Featuring an interview with Dr Shannon N Westin, including the following topics: Biomarker testing and utility in ovarian cancer (OC) (0:00) Selection of a PARP inhibitor for the treatment of OC (9:18) Addition of immunotherapy to up-front treatment of OC (15:50) Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10) Selection of treatment for recurrent OC (21:46) Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22) Adjuvant therapy for EC (32:28) Utility of lenvatinib/pembrolizumab in EC (35:08) Clinical findings supporting the potential use of selinexor for EC (39:42) Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22) Management of adverse effects associated with T-DXd (49:49) CME information and select publications

Show notes and links: https://www.chrisbeatcancer.com/from-hospice-to-healed-julie-masons-endometrial-cancer-journey

Featuring perspectives from Prof Susana Banerjee and Dr Ursula Matulonis, including the following topics: Introduction: Tale of Two Cities — ASCO 2025 (0:00) Ovarian Cancer (11:20) HER2-Positive Gynecologic Cancers (31:28) Endometrial Cancer (40:16) Cervical Cancer (51:14) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 2: Endometrial Cancer and Cervical Cancer — Susana Banerjee, MBBS, MA, PhD CME information and select publications

In this episode, we review the high-yield topic ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Endometrial Cancer ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley, Dr Ritu Salani, Dr Alessandro D Santin and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Introduction (0:00) Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Liu (2:00) Current Management of Relapsed/Refractory (R/R) OC; Promising Novel Agents and Strategies Under Investigation — Dr O'Malley (27:23) Role of HER2-Targeted Therapy in Advanced OC, Endometrial Cancer (EC) and Other Gynecologic Cancers — Dr Santin (50:22) First-Line Therapy for Advanced EC — Dr Westin (1:15:00) Current Therapeutic Options for R/R EC; Novel Investigational Strategies for Newly Diagnosed and Recurrent Disease — Dr Salani (1:36:45) CME information and select publications  

Featuring perspectives from Ms Kathryn M Lyle, Dr Ritu Salani, Ms Jaclyn Shaver and Dr Brian M Slomovitz, including the following topics: Introduction: Overview of Endometrial Cancer (0:00) First-Line Therapy for Advanced or Recurrent Endometrial Cancer (11:01) Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced Endometrial Cancer (39:09) Novel Investigational Strategies for Newly Diagnosed Advanced Endometrial Cancer (1:00:15) Incidence and Management of HER2-Positive Endometrial Cancer (1:17:52) NCPD information and select publications  

Why are Black women are less likely to survive endometrial cancer? It's a deep-seated inequality, and Dr Kemi Doll has been treating patients and studying it for years. She explains what endometrial cancer is, why this lethal disparity exists, and why she thinks Black women are the ‘canary in the coal mine' in women's health. Show Notes:More about Dr Kemi Doll - https://www.uwmedicine.org/bios/kemi-dollMore about endometrial cancer - https://www.cancer.org/cancer/types/endometrial-cancer/about/what-is-endometrial-cancer.htmlSubscribe to our newsletter for more on this episode: https://overlookedpodcast.kit.com/e4b85028b6Want more Overlooked? Listen to this episode about mapping the ovaries next: https://overlooked.simplecast.com/episodes/mapping-the-ovaries-with-dr-kathleen-e-oneill LIKE WHAT YOU HEAR? Support the show by:- Leaving a review on Apple, Spotify, or wherever you're listening.- Becoming a Patron - Overlooked is on Patreon, where you can and get rewards like merch, the ability to send in questions for expert guests, and a 'backstage pass' to the show. New to Overlooked? Welcome. Overlooked was launched in 2023 to tell the story of ovarian cancer through one woman's story. In 2024 the show started to cover other overlooked topics in women's health - and there are many. The show is hosted by Golda Arthur, an audio journalist and producer. EMAIL US: hello@overlookedpod.com FOLLOW US:Instagram https://www.instagram.com/overlookedpod/LinkedIn https://www.linkedin.com/company/105541285/admin/dashboard/ LEARN MORE: https://overlookedpod.com/ DISCLAIMER What you hear and read on ‘Overlooked' is for general information purposes only and represents the opinions of the host and guests. The content on the podcast and website should not be taken as medical advice. Every person's body is unique, so please consult your healthcare professional for any medical questions that may arise.

Featuring perspectives from Dr David M O'Malley and Dr Brian M Slomovitz, including the following topics: Ovarian Cancer; HER2-Directed Therapy for Advanced Gynecologic Cancers — Dr O'Malley (0:00) Endometrial Cancer and Cervical Cancer — Dr Slomovitz (23:38) CME information and select publications

Editor's choice: A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG studyEditorial: Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equityHosted by:Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic OncologyFeaturing:V.L. Bae-Jump, University of North Carolina at Chapel Hill, Chapel Hill, NC, USABrian M. Slomovitz, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mount Sinai Medical Center, Miami Beach, FLCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net